文献速递炎症性肠病

炎症性肠病的整体医疗:是时候采用以患者为中心的方法了吗?

Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
PubMed 文献 · Gut · 2022-09-28

炎症性肠病(IBD)是一种以胃肠道慢性炎症为特征的全球新兴疾病,常伴肠外症状并影响患者心理情绪。尽管治疗有进展,仅三分之一接受获批药物治疗的患者达到短期至中期缓解。本文通过系统综述评估补充替代疗法和饮食治疗对临床缓解、内镜缓解、分子标志物调节或生活质量指标中至少一项的疗效,识别可能适合临床采用和进一步大规模随机临床试验的候选方案,并提出以患者为中心的临床照护模型和系列建议。

要点

  • IBD为全球新兴疾病,仅三分之一接受获批药物治疗的患者达到短期至中期缓解。
  • 系统综述纳入随机临床试验,评估补充替代疗法和饮食治疗对四项结局中至少一项的疗效。
  • 通过指出结局内和结局间一致性,识别可能适合临床采用和进一步研究的候选方案。

核心结论

  • 通过指出结局内和结局间一致性,识别出可能适合临床采用和进一步大规模随机临床试验研究的候选方案,涵盖IBD广泛异质性。
  • 提出以患者为中心的临床照护模型和面向利益相关者的系列建议,特别关注补充替代方法和饮食策略,旨在实现整体缓解。

研究设计与样本

  • 一项精心实施的文献综述,纳入评估补充替代方法和饮食治疗疗效的随机临床试验。

主要发现

  • 仅三分之一的诊断患者接受获批药物治疗后达到短期至中期缓解。
  • 未成功治疗的患者可能自行使用补充替代方法管理症状,无论是否咨询治疗医生。
  • 此类方法可能存在未知不良反应和与医学批准疗法相互干扰的风险。

关键数值与推荐

  • 纳入的随机临床试验评估补充替代方法和饮食治疗对以下四项结局中至少一项的疗效:临床缓解、内镜缓解、分子生物标志物调节或生活质量指标。

临床怎么用

  • 提出以患者为中心的临床照护模型和面向利益相关者的系列建议,特别关注补充替代方法和饮食策略,旨在实现整体缓解。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammatory bowel disease (IBD) is an emerging global disease characterised by chronic inflammation of the gastrointestinal tract. However, IBD is also manifested by several extraintestinal symptoms which, along with the intestinal symptoms, impact on the mental and emotional well-being of patients. Despite therapeutic advancements, only one-third of the diagnosed patients receiving approved medical treatments achieve short-term to medium-term remission. Consequently, patients who do not get successfully treated might resort to using complementary and alternative approaches to manage their symptoms, with or without consulting their treating clinician. Despite their possible potential, such approaches have various risks stemming from unknown adverse reactions and possible interference with medically approved therapies. In this study, we present the results of a well-performed literature review where we included randomised clinical trials which have assessed the efficacy of complementary approaches and dietary therapy on at least one of the following four outcomes: clinical remission, endoscopic remission, modulation of molecular biomarkers or quality of life metrics. By pointing out intraoutcome and interoutcome concordance, we identified possible candidates for clinical adoption and further study in larger randomised clinical trials covering the broad spectrum of IBD heterogeneity. We finally proposed a patient-centric clinical care model and a series of recommendations for stakeholders, with special attention to complementary approaches and dietary strategies, aimed at achieving holistic remission.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sudhakar P, Wellens J, Verstockt B, et al. Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut. 2022. PMID: 36171081. doi:10.1136/gutjnl-2022-328221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。